MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders, built on its proprietary PEPs platform. Lead programs include canvuparatide (MBX 2109) for hypoparathyroidism, plus MBX 4291, MBX 5765, and MBX 6XXX. - View it on GitHub